CytomX Therapeutics, Inc. (NASDAQ:CTMX) major shareholder Robert I. Tepper sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $18.00, for a total transaction of $360,000.00. Following the completion of the sale, the insider now owns 54,293 shares in the company, valued at approximately $977,274. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down 0.45% during mid-day trading on Thursday, reaching $17.57. 97,603 shares of the company’s stock traded hands. The stock has a 50 day moving average of $15.48 and a 200 day moving average of $15.31. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $20.02. The company’s market cap is $647.75 million.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The company had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $4.95 million. On average, equities research analysts predict that CytomX Therapeutics, Inc. will post ($1.49) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “CytomX Therapeutics, Inc. (CTMX) Major Shareholder Robert I. Tepper Sells 20,000 Shares” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/21/cytomx-therapeutics-inc-ctmx-major-shareholder-robert-i-tepper-sells-20000-shares.html.

CTMX has been the subject of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $25.00 price objective on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Wedbush initiated coverage on shares of CytomX Therapeutics in a research report on Thursday, September 7th. They issued an “outperform” rating and a $26.00 price objective for the company. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. CytomX Therapeutics has an average rating of “Hold” and a consensus target price of $25.67.

A number of institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in CytomX Therapeutics by 27.8% during the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock valued at $797,000 after purchasing an additional 11,200 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in CytomX Therapeutics by 36.9% during the second quarter. The Manufacturers Life Insurance Company now owns 23,529 shares of the biotechnology company’s stock valued at $365,000 after purchasing an additional 6,342 shares in the last quarter. Redmile Group LLC raised its stake in CytomX Therapeutics by 2.4% during the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock valued at $10,825,000 after purchasing an additional 16,500 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in CytomX Therapeutics during the second quarter valued at $174,000. Finally, State Street Corp raised its stake in CytomX Therapeutics by 58.8% during the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after purchasing an additional 165,342 shares in the last quarter. 59.97% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.